A detailed history of Pfm Health Sciences, LP transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Pfm Health Sciences, LP holds 4,306,671 shares of CRBU stock, worth $7.28 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares
4,306,671
Previous 4,083,372 5.47%
Holding current value
$7.28 Million
Previous $6.7 Million 25.42%
% of portfolio
0.49%
Previous 0.34%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.56 - $2.73 $348,346 - $609,606
223,299 Added 5.47%
4,306,671 $8.4 Million
Q2 2024

Aug 14, 2024

SELL
$1.62 - $5.05 $3.89 Million - $12.1 Million
-2,399,898 Reduced 37.02%
4,083,372 $6.7 Million
Q1 2024

May 14, 2024

BUY
$4.82 - $8.26 $12,078 - $20,699
2,506 Added 0.04%
6,483,270 $33.3 Million
Q4 2023

Feb 14, 2024

SELL
$3.58 - $6.25 $873,344 - $1.52 Million
-243,951 Reduced 3.63%
6,480,764 $37.1 Million
Q3 2023

Nov 14, 2023

BUY
$4.08 - $8.14 $4.71 Million - $9.39 Million
1,153,846 Added 20.71%
6,724,715 $32.1 Million
Q2 2023

Aug 14, 2023

BUY
$4.04 - $5.47 $2.26 Million - $3.06 Million
558,751 Added 11.15%
5,570,869 $23.7 Million
Q1 2023

May 15, 2023

BUY
$4.3 - $7.78 $2.38 Million - $4.3 Million
552,335 Added 12.38%
5,012,118 $26.6 Million
Q4 2022

Feb 14, 2023

SELL
$5.57 - $11.01 $8.58 Million - $17 Million
-1,540,217 Reduced 25.67%
4,459,783 $28 Million
Q2 2022

Aug 15, 2022

BUY
$5.1 - $9.74 $8.31 Million - $15.9 Million
1,629,455 Added 37.28%
6,000,000 $32.6 Million
Q1 2022

May 16, 2022

BUY
$8.42 - $15.32 $2.34 Million - $4.26 Million
278,236 Added 6.8%
4,370,545 $40.1 Million
Q3 2021

Nov 15, 2021

BUY
$15.75 - $30.29 $64.5 Million - $124 Million
4,092,309 New
4,092,309 $88.2 Million

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $103M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Pfm Health Sciences, LP Portfolio

Follow Pfm Health Sciences, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

News

Stay updated on Pfm Health Sciences, LP with notifications on news.